Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

Daniella M. Schwartz(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Michael Bonelli(Medical University of Vienna), Massimo Gadina(National Institute of Arthritis and Musculoskeletal and Skin Diseases), John J. O’Shea(National Institute of Arthritis and Musculoskeletal and Skin Diseases)
Nature Reviews Rheumatology
December 3, 2015
10.1038/nrrheum.2015.167
Cited by 636Open Access
Full Text

Abstract

Related Papers

Immunomodulatory functions of type I interferons
José M. González‐Navajas, Jong‐Dae Lee, Michael David et al.|Nature reviews. Immunology|2012|1k
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn, Subrata Ghosh, Julián Panés et al.|New England Journal of Medicine|2012|796
Growth Hormone Insensitivity Associated with a<i>STAT5b</i>Mutation
Eric M. Kofoed, Vivian Hwa, Brian M. Little et al.|New England Journal of Medicine|2003|524
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
William J. Sandborn, Subrata Ghosh, Julián Panés et al.|Clinical Gastroenterology and Hepatology|2014|298
IL‐10 and IL‐10 receptor defects in humans
Erik‐Oliver Glocker, Daniel Kotlarz, Christoph Klein et al.|Annals of the New York Academy of Sciences|2011|269